Article
Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the AblT315I mutant kinase to combat imatinib resistance in chronic myeloid leukemia.
Medical oncology (Northwood, London, England) - 3 Oct 2023
Al Shahrani Mesfer, Gahtani Reem M, Abohassan Mohammad, Alasmari Sultan, Makkawi Mohammed
Abstract excerpt
The discovery of imatinib, a specific inhibitor of Abl kinase, revolutionized the therapeutic approach to chronic myeloid leukemia (CML); however, its efficacy can be impeded by the emergence of novel mutations within the kinase domain, particularly AblT315I, that lead to the development of drug resistance. It therefore remains necessary to identify specific inhibitors that can effectively target...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.